Carvolix SA (EPA:CVX)
3.500
-0.080 (-2.23%)
At close: Feb 24, 2026
Carvolix Revenue
Carvolix had revenue of 577.00K EUR in the half year ending June 30, 2025, a decrease of -2.20%. This brings the company's revenue in the last twelve months to 5.27M, up 306.64% year-over-year. In the year 2024, Carvolix had annual revenue of 5.35M with 337.09% growth.
Revenue (ttm)
5.27M
Revenue Growth
+306.64%
P/S Ratio
26.75
Revenue / Employee
69.29K
Employees
76
Market Cap
140.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.35M | 4.13M | 337.09% |
| Dec 31, 2023 | 1.22M | -115.00K | -8.59% |
| Dec 31, 2022 | 1.34M | -112.00K | -7.72% |
| Dec 31, 2021 | 1.45M | 627.00K | 76.09% |
| Dec 31, 2020 | 824.00K | -605.00K | -42.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guerbet | 820.92M |
| Eurobio Scientific Société anonyme | 162.47M |
| Biosynex | 97.95M |
| Diagnostic Medical Systems | 49.47M |
| Median Technologies | 23.38M |
| Novacyt | 22.69M |
| Implanet | 11.10M |
| Mauna Kea Technologies | 8.18M |